WEBULL
WebtradeDownload

Adaptive Biotechnologies (ADPT) Heads To Boston Conference, Is Fair Value Above $26.64?

Simply Wall St · 3d ago

Adaptive Biotechnologies (ADPT) heads into the Longwood Healthcare Leaders Boston CEO conference today, where Chief Commercial Officer Sharon Benzeno is scheduled to speak about the immune medicine business at 4:10 p.m. local time.

At a share price of US$26.64, Adaptive Biotechnologies has had a mixed few weeks, with a 1-day share price return that fell 5.43% and a 30-day share price return down 6.03%. However, a 90-day share price return of 8.51% and a year-to-date share price return of 67.44% signal that momentum has built over 2026, supported by a 1-year total shareholder return of 53.63% and a very large 3-year total shareholder return, even though the 5-year total shareholder return declined 27.01%.

Scan beyond Adaptive Biotechnologies and size up other immune medicine and biotech players with our hand picked 34 healthcare AI stocks that are riding similar conference and clinical momentum.

After a sharp year to date climb and a recent pullback, Adaptive Biotechnologies now trades between a modest discount to analyst targets and a premium to some intrinsic estimates. Where does fair value realistically land along that spectrum?

Most Popular Narrative: 11% Undervalued

With Adaptive Biotechnologies last trading at $26.64 against a widely followed fair value estimate of $29.81, the prevailing narrative frames the stock as modestly underpriced while still highly sensitive to execution in minimal residual disease testing and immune medicine.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and indicates the potential for operating leverage and expanding net margins if revenue continues to rise.

See why 8 investors see Adaptive Biotechnologies as 11% undervalued.

Result: Fair Value of $29.81 (UNDERVALUED)

Still, the picture for Adaptive Biotechnologies can shift quickly if reimbursement policy turns less favorable or if key partnerships, such as its collaboration with Genentech, underperform expectations.

Find out about the key risks to this Adaptive Biotechnologies narrative.

Another View: SWS DCF Puts Adaptive Biotechnologies In A Different Bucket

The first story on Adaptive Biotechnologies leans on analyst targets and a fair value of $29.81 to argue the shares look about 11% undervalued. A second lens tells something else. The SWS DCF model estimates future cash flows at $23.33 per share, which leaves the current $26.64 price looking expensive instead. Which yardstick do you trust more when real cash generation is still in front of the business?

Look into how the SWS DCF model arrives at its fair value.

ADPT Discounted Cash Flow as at Nov 2026
ADPT Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Adaptive Biotechnologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 33 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Adaptive Biotechnologies so far, right? Act while the data is fresh and weigh both sides by reviewing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Adaptive Biotechnologies?

Do not stop at Adaptive Biotechnologies. Broaden your watchlist now, compare different return profiles, and give yourself more options before the next big move in the market.